ABERA: Secured funding and positive R&D milestones drive clinical progress despite ongoing losses

About this update from Abera Bioscience Ab

Strong progress in vaccine R&D, with secured financing and grants supporting clinical advancement of pneumococcal and influenza candidates. Q3 saw higher grant income but continued net losses, with a robust cash position and equity base.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Abera Bioscience Ab